2-chloro-N,6-dimethylpyridin-4-amine | 1439923-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-chloro-N,6-dimethylpyridin-4-amine
• CAS: 1439923-20-2
• 化学式: C₇H₉ClN₂
• 分子量: 156.615
• InChiKey: SHQFJHPZIHKEIU-UHFFFAOYSA-N

物化性质

• 沸点：
  270.6±35.0 °C(Predicted)
• 密度：
  1.201±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-chloro-N,6-dimethylpyridin-4-amine 在 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1‘-biphenyl)-2-(2‘-amino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 potassium carbonate 、 caesium carbonate 作用下， 以 二甲基亚砜 、 乙腈 为溶剂， 反应 24.0h， 生成 [7-[[6-methyl-4-(methylamino)-2-pyridyl]amino]-2,3-dihydro-1,4-benzodioxin-5-yl]trifluoromethanesulfonate
  参考文献：
  名称：

  [EN] NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF
  [FR] NOUVEAUX MODULATEURS DE L'EHMT1 ET DE L'EHMT2 ET LEUR UTILISATION THÉRAPEUTIQUE

  摘要：

  Described herein are novel compounds, compositions and methods for modulating EHMT1 and EHMT2 and treatment of diseases including cancer using such compounds, compositions, and methods.

  公开号：

  WO2023064586A1
• 作为产物：
  描述：

  2,4-二氯-6-甲基吡啶 、 甲胺 以 乙醇 为溶剂， 生成 2-chloro-N,6-dimethylpyridin-4-amine
  参考文献：
  名称：

  [EN] NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF
  [FR] NOUVEAUX MODULATEURS DE L'EHMT1 ET DE L'EHMT2 ET LEUR UTILISATION THÉRAPEUTIQUE

  摘要：

  Described herein are novel compounds, compositions and methods for modulating EHMT1 and EHMT2 and treatment of diseases including cancer using such compounds, compositions, and methods.

  公开号：

  WO2023064586A1

文献信息

• [EN] AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS<br/>[FR] COMPOSÉS ARYLE OU HÉTÉROARYLE À SUBSTITUTION AMINE UTILISÉS COMME INHIBITEURS DE EHMT1 ET EHMT2
  申请人：EPIZYME INC

  公开号：WO2017181177A1

  公开（公告）日：2017-10-19

  The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开涉及氨基取代的芳基或杂芳基化合物。本公开还涉及包含这些化合物的药物组合物，以及通过向需要治疗的受试者施用本公开的氨基取代的芳基或杂芳基化合物或其药物组合物，来治疗疾病（例如，镰状细胞性贫血）的方法，该方法通过抑制从EHMT1和EHMT2选择的甲基转移酶酶。本公开还涉及将此类化合物用于研究或其他非治疗目的。
• Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase
  作者：Reema K. Thalji、Jeff J. McAtee、Svetlana Belyanskaya、Martin Brandt、Gregory D. Brown、Melissa H. Costell、Yun Ding、Jason W. Dodson、Steve H. Eisennagel、Rusty E. Fries、Jeffrey W. Gross、Mark R. Harpel、Dennis A. Holt、David I. Israel、Larry J. Jolivette、Daniel Krosky、Hu Li、Quinn Lu、Tracy Mandichak、Theresa Roethke、Christine G. Schnackenberg、Benjamin Schwartz、Lisa M. Shewchuk、Wensheng Xie、David J. Behm、Stephen A. Douglas、Ami L. Shaw、Joseph P. Marino

  DOI：10.1016/j.bmcl.2013.04.019

  日期：2013.6

  1-(1,3,5-Triazin-yl)piperidine-4-carboxamide inhibitors of soluble epoxide hydrolase were identified from high through-put screening using encoded library technology. The triazine heterocycle proved to be a critical functional group, essential for high potency and P450 selectivity. Phenyl group substitution was important for reducing clearance, and establishing good oral exposure. Based on this lead optimization work, 1-[4-methyl-6-(methylamino)-1,3,5-triazin-2-yl]-N-[[4-bromo-2-(trifluoromethoxy)]-phenyl]methyl}-4-piperidinecarboxamide (27) was identified as a useful tool compound for in vivo investigation. Robust effects on a serum biomarker, 9, 10-epoxyoctadec-12(Z)-enoic acid (the epoxide derived from linoleic acid) were observed, which provided evidence of robust in vivo target engagement and the suitability of 27 as a tool compound for study in various disease models. Published by Elsevier Ltd.
• AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS AS EHMT1 AND EHMT2 INHIBITORS
  申请人：Epizyme Inc

  公开号：EP3442947A1

  公开（公告）日：2019-02-20
• AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
  申请人：Epizyme, Inc.

  公开号：US20170355712A1

  公开（公告）日：2017-12-14

  The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.